Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Voting Common Shares, no par value
-
Shares outstanding
-
51.9M
-
Number of holders
-
37
-
Total 13F shares, excl. options
-
3.78M
-
Shares change
-
-1.9M
-
Total reported value, excl. options
-
$16.9M
-
Value change
-
-$12.6M
-
Put/Call ratio
-
7.14
-
Number of buys
-
21
-
Number of sells
-
-15
-
Price
-
$4.45
Significant Holders of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) as of Q2 2021
49 filings reported holding DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value as of Q2 2021.
DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) has 37 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.78M shares
of 51.9M outstanding shares and own 7.29% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (786K shares), Manatuck Hill Partners, LLC (571K shares), Stonepine Capital Management, LLC (420K shares), Ikarian Capital, LLC (415K shares), JACOB ASSET MANAGEMENT OF NEW YORK LLC (275K shares), Corriente Advisors, LLC (204K shares), MARSHALL WACE, LLP (156K shares), BANK OF MONTREAL /CAN/ (143K shares), GEODE CAPITAL MANAGEMENT, LLC (134K shares), and RENAISSANCE TECHNOLOGIES LLC (94.1K shares).
This table shows the top 37 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.